BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11309552)

  • 1. Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation.
    Kubli S; Feihl F; Waeber B
    Clin Pharmacol Ther; 2001 Apr; 69(4):238-44. PubMed ID: 11309552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
    Gupta S; Wright HM
    Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection.
    Mahmud A; Feely J
    Am J Hypertens; 2008 Jun; 21(6):663-7. PubMed ID: 18437130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of nebivolol, atenolol and propranolol on in vivo cardiovascular and metabolic responses to isoproterenol in dogs.
    Bowden CR; Marchione CS
    J Pharmacol Exp Ther; 1989 Nov; 251(2):599-605. PubMed ID: 2572694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
    J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade.
    Cosentino F; Bonetti S; Rehorik R; Eto M; Werner-Felmayer G; Volpe M; Lüscher TF
    J Hypertens; 2002 Mar; 20(3):421-8. PubMed ID: 11875309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nebivolol on cardiovascular changes associated with a rat model of insulin-resistance.
    Renna N; Risler N; Cruzado M; Gonzalez S; Lama C; Miatello RM
    Cell Mol Biol (Noisy-le-grand); 2005 Nov; 51(6):531-7. PubMed ID: 16309577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring vascular benefits of endothelium-derived nitric oxide.
    Cockcroft JR
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):177S-183S. PubMed ID: 16373196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats.
    Toblli JE; Cao G; Casas G; Mazza ON
    Am J Hypertens; 2006 Dec; 19(12):1226-32. PubMed ID: 17161767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
    Tzemos N; Lim PO; MacDonald TM
    Circulation; 2001 Jul; 104(5):511-4. PubMed ID: 11479245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
    Ignarro LJ
    Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery.
    Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
    Eur J Pharmacol; 2005 Jan; 508(1-3):159-66. PubMed ID: 15680267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.
    Chlopicki S; Kozlovski VI; Gryglewski RJ
    J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):615-24. PubMed ID: 12512696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.
    Mason RP; Kubant R; Jacob RF; Walter MF; Boychuk B; Malinski T
    J Cardiovasc Pharmacol; 2006 Jul; 48(1):862-9. PubMed ID: 16891916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
    Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
    Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
    Ignarro LJ
    Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress.
    Arosio E; De Marchi S; Prior M; Zannoni M; Lechi A
    J Hypertens; 2002 Sep; 20(9):1793-7. PubMed ID: 12195121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide mediated venodilator effects of nebivolol.
    Bowman AJ; Chen CP; Ford GA
    Br J Clin Pharmacol; 1994 Sep; 38(3):199-204. PubMed ID: 7826820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of aspirin and various iontophoresis solution vehicles on skin microvascular reactivity.
    Abou-Elenin K; Xydakis A; Hamdy O; Economides PA; Horton ES; Veves A
    Microvasc Res; 2002 Jan; 63(1):91-5. PubMed ID: 11749076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
    Prisant LM
    J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.